Armistice Capital’s Redhill Biopharma RDHL Stock Holding History

Armistice Capital’s Portfolio RDHL Stock Details RDHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-28,916	Closed	-$369K	–	352
2023 Q3	$369K	Buy	+28,916	New	+$756K	0.01%	176
2023 Q2	–	Sell	-10,400	Closed	-$1.06M	–	263
2023 Q1	$1.06M	Buy	+10,400	New	+$1.96M	0.02%	138

Other funds holding RDHL

Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

MOS

MGO One Seven Beachwood, Ohio $6.06B AUM 28.9% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

APC

Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

Armistice Capital's RDHL Position: Q4 2023 in Review

Armistice Capital sold out of Redhill Biopharma (RDHL) in Q4 2023, closing a stake of 28,916 shares — an estimated $369K sold.

Armistice Capital first reported a position in RDHL in Q1 2023 and held it in 2 quarters. The position peaked at $1.06M in Q1 2023. 17 funds tracked by Wall St. Rank hold RDHL as of Q4 2023.

Armistice Capital reported no remaining Redhill Biopharma position as of Q4 2023 after selling out during the quarter.
Armistice Capital sold 28,916 Redhill Biopharma shares in Q4 2023, an estimated $369K.
Armistice Capital first reported a position in Redhill Biopharma in Q1 2023 and held it in 2 quarters.
Armistice Capital's Redhill Biopharma position peaked at $1.06M in Q1 2023.
17 funds tracked by Wall St. Rank held Redhill Biopharma as of Q4 2023.

Based on Armistice Capital's 13F filing for Q4 2023, filed 13 Feb 2024.